The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography

Not Applicable

Completed

• Conditions: Blood Pressure
• Interventions: Drug: stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure; Drug: ACE/ARB stopped 24 hours before procedure and start immediately after

• Registration Number: NCT01071642
• Lead Sponsor: Soroka University Medical Center

Brief Summary

The aim of the current study is to evaluate prospectively whether concomitant administration of RAAS blockers (namely ACE-I and ARBs') influence the change in estimated GFR (eGFR) after administration of contrast media in patients undergoing non-emergent coronary angiography.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-02-18
• Study First Submitted QC: 2010-02-18
• Study First Posted: 2010-02-19
• Study Start: 2010-03
• Primary Completion: 2010-09
• Study Completion: 2010-11
• Status Verified: 2017-06
• Last Update Submitted: 2017-06-20
• Last Update Posted: 2017-06-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• 1. Age>18 years
• 2. Subjects on chronic therapy with ACE-I and/or ARBs' (confirmed by electronic records in their medical file)
• 3. Subjects planned to undergo non-emergent coronary angiography.
• 4. Signed informed consent

Exclusion Criteria

• 1. eGFR<30 ml/min at baseline
• 2. Chronic utilization of NSAIDS and Cox-2 selective inhibitors
• 3. Chronic treatment with mineralocorticosteroid receptor blocker
• 4. Systolic blood pressure<90 mmHg
• 5. Planned staged (repeated) procedure within 48 hours
• 6. Administration of contrast within 14 days prior to the enrollment
• 7. contraindication to stop ACE-I or ARB'S

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
group b	stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure	-
group c	ACE/ARB stopped 24 hours before procedure and start immediately after	-

Primary Outcome Measures

Name	Time	Method
Change in eGFR from baseline to 48 hours following the exposure to the contrast.	48 hours after exposure to the contrast

Secondary Outcome Measures

Name	Time	Method
1. Rate of eGFR decrease>25% from the baseline, 2. Length of hospitalization,	48-72 hours after exposure to contrast

Trial Locations

Locations (1)

Talya Wolak; 🇮🇱 Bear Sheva, Israel